Biotech outperformance expected to continue in 2026, Baird analysts say

Baird projects continued biotech outperformance in 2026, citing strong sector fundamentals such as robust drug development, favorable clinical data, improved FDA filings, early-stage M&A and a rotation of capital into higher-beta biotech names. The firm highlighted that the SPDR S&P Biotech ETF rallied roughly 75% from its April 8, 2025 lows versus a 37% gain for the S&P 500 over the same period, and listed top picks including Biogen (BIIB), Xenon, Biohaven, Immutep, Taysha, Voyager (VYGR), Ocular Therapeutix, Syros and Celyad. Baird acknowledged downside risks—rising interest rates, regulatory and pricing headlines, AI competition for capital and company-specific clinical setbacks—but judged sector fundamentals supportive of further upside and M&A-driven value realization.

Analysis

Market structure: winners are late‑stage and mid‑cap biotech names with credible catalysts (BIIB, XENE, BHVN) and large pharma acquirers willing to pay premiums to fill looming LOE holes; losers are cash‑burn discovery names and SPAC-era microcaps without near‑term readouts. The 75% rebound in the SPDR S&P Biotech ETF from April lows signals active risk‑on flows and shrinking float via M&A that can amplify rallies but also concentrate single‑name risk.

Risk assessment: Tail risks include a regulatory shock (FDA policy shift or adverse advisory panel) or a rapid 75–100bp move higher in 10‑yr yields within 3 months that re‑rates long‑duration biotech cashflows. Immediate moves will be binary around readouts (days), mid‑term (weeks/months) driven by M&A rumors and financing windows, and long‑term (quarters/years) tied to LOE cliffs and sustained rates; hidden dependency is big‑pharma balance sheets and willingness to deploy >$50–100bn annually into external R&D.

Trade implications: Implement concentrated, catalyst‑driven longs (1–3% positions) in BIIB, XENE, BHVN and a tactical XBI core position hedged with puts if rates breach 4.25% on the 10‑yr. Use 6–12 month call spreads into binary events to limit premium; pair long mid‑cap with short microcap basket to neutralize beta and idiosyncratic funding risk. Enter on measured breakouts or 5–15% pullbacks; take profits after 40–60% moves or post‑M&A.

Contrarian angles: Consensus underestimates the speed at which capital can exit biotech if macro or drug‑pricing headlines re‑ignite; the 2H2025 catch‑up could be overdone relative to late‑stage pipeline quality. Historical parallels (post‑2015 biotech rallies) show quick gains followed by multi‑quarter mean reversion when financing tightens, so avoid size concentrations and expect higher implied volatility ahead of FDA/readouts.

Key Decisions for Investors

• Establish a staggered 2–3% long core position in XBI (SPDR S&P Biotech ETF) over 2–4 weeks; simultaneously buy 3–6 month at‑the‑money puts sized to 20% of notional if the 10‑yr yield rises above 4.25% or XBI drops 12% from entry.
• Take a 1–2% long position in BIIB (Biogen) as a strategic M&A/defensive biotech play; add another 1% on a pullback of ≥10%; set a 12‑month target of +30–50% and a stop‑loss at −18% from entry to limit downside.
• Deploy 0.5–1% directional catalyst trades in XENE and BHVN each using 9–12 month call spreads (buy ATM call, sell 40–60% OTM) ahead of expected clinical readouts to cap premium and retain upside; close or roll 7–14 days after readout.
• Implement a relative‑value pair: long 1% BHVN (or XENE) vs short 1% OCUL (or a microcap biotech basket of 6–8 names with <12 months runway) to capture catalyst dispersion and fund‑raising/failure risk; rebalance if spread compresses >25% or if either side gaps >30% intraday.